Graves Disease at Nine Weeks of Gestation on Methimazole
A 29-year-old woman who is 9 weeks pregnant presents with palpitations, heat intolerance, and a 6 kg weight loss over two months. She has a diffuse goiter and a mild tremor. Pulse is 118 and regular, blood pressure 132/70 mmHg, and she has no eye signs. TSH is less than 0.01 mIU/L, free T4 is 3.4 ng/dL (reference 0.8-1.8), free T3 is elevated, and TSH-receptor antibodies are positive. She was started on methimazole 10 mg daily four weeks ago by another physician, and her symptoms have only partly improved. She takes no other medication, has no known liver disease, and has a normal complete blood count. She is anxious about the effect of treatment on the pregnancy and asks whether she can simply stop the drug until after delivery.
1. What is your immediate drug management, and what thyroid function target would you aim for?
Read the worked answer
She has untreated or undertreated Graves disease in the first trimester, and stopping treatment is not an option: uncontrolled thyrotoxicosis increases the risk of miscarriage, preterm birth, preeclampsia, heart failure, and thyroid storm. However, methimazole in the first trimester is associated with methimazole embryopathy (aplasia cutis, esophageal and choanal atresia, omphalocele), so the correct move is to stop methimazole now and switch to propylthiouracil, approximately 100-150 mg three times daily (about 300-450 mg/day) depending on weight and severity, with dose adjustment according to free T4.
The treatment target in pregnancy is different from that in non-pregnant patients: keep free T4 at or slightly above the upper limit of the reference range (roughly 1.5-1.8 ng/dL) and do not attempt to normalize TSH, because over-treatment causes fetal hypothyroidism and goiter. Do not use a block-replace regimen with levothyroxine in pregnancy. For symptomatic tachycardia, propranolol 10-20 mg every 6-8 hours can be used for a few weeks and then tapered; avoid atenolol. Radioiodine is absolutely contraindicated. Reserve thyroidectomy for drug intolerance or non-compliance, ideally in the second trimester.
2. What monitoring and adverse-effect counseling does she need, and what is the drug plan across the trimesters?
Read the worked answer
Obtain baseline liver enzymes and a complete blood count before or at the time of the switch. Check free T4 and TSH every 2-4 weeks until stable, then every 4-6 weeks, and check a CBC and liver panel every 2-4 weeks initially. Counsel her explicitly to stop the drug and seek urgent testing if she develops fever or sore throat (agranulocytosis, roughly 0.2-0.5% of patients) or jaundice, dark urine, or right upper quadrant pain (propylthiouracil hepatotoxicity, including rare fulminant failure). Propylthiouracil can also cause ANCA-associated vasculitis.
The plan is trimester-based: propylthiouracil through the end of the first trimester (roughly 13-16 weeks), then switch back to methimazole at the lowest effective dose, because propylthiouracil carries a higher risk of hepatotoxicity and methimazole is preferred outside organogenesis. Continue the lowest dose that keeps free T4 at or just above the upper normal range. Involve obstetrics and consider maternal-fetal medicine co-management, and monitor for preeclampsia, which is more common in Graves pregnancy.
3. What fetal and neonatal risks must be addressed before delivery?
Read the worked answer
TSH-receptor antibodies cross the placenta and can stimulate the fetal thyroid, causing fetal thyrotoxicosis with tachycardia over 160 beats per minute, growth restriction, goiter, and hydrops; the risk persists for the whole pregnancy and even if the mother is well controlled or has had prior definitive therapy. Check TSH-receptor antibody levels in the third trimester, since a high level predicts neonatal Graves disease, and perform serial fetal growth and heart-rate assessment with ultrasound in the third trimester.
Conversely, over-treatment with antithyroid drugs in late pregnancy can cause fetal goiter and hypothyroidism, which is why the free T4 target is at or slightly above the upper normal limit and the dose is minimized. Tell the neonatal team before delivery so the baby is examined for goiter, tachycardia, and heart failure, and so cord blood and day 3-5 thyroid function can be checked; neonatal Graves disease may appear days after birth as maternal drug clears. Delivery should occur where neonatal intensive care is available. Also recognize that labor, infection, and preeclampsia can precipitate thyroid storm, so continue antithyroid therapy through delivery.